Life science companies are on a mission to bring life-saving medicines and products to market as quickly and safely as possible. Yet, doing so requires jumping through necessary regulatory hoops. Without immediate access to intelligent data, making sure FDA submissions are compliant will be more complicated than necessary.
Daunting Data Capture
One of the most challenging aspects of preparing data for FDA consideration is capturing the thousands of documents that are required for submissions. The information may come from dozens of internal and external sources and in hundreds of different formats. If FDA submission materials are incomplete or incorrect it may significantly delay approval processes.
The Role of Searchability
To meet regulatory expectations, pharmaceutical companies must be able to find what is expected. However, a significant portion of pharmaceutical data is unstructured, which means it isn’t searchable. The application of high-accuracy OCR to anything that is non-searchable is a highly effective way to create documents that can be easily found, shared, and organized. It is easier to surface relevant information when documents are grouped by type, indexed, and metadata-tagged. Ultimately, searchable documents are an integral part of a high-quality submission that reviewers at the FDA or EMEA (Europe) can easily navigate.FDA Requirements
Proper Formatting Matters
The FDA, and other regulatory agencies, also have specific PDF guidelines that dictate structure, how documents are formatted, their size, and how they are packaged. Automation technology developed for Life Sciences' unique needs enables companies to assemble and format hyperlinks and bookmarks, with navigation-rich content, resulting in submission-ready PDFs for FDA approval. The high quality means that new life-saving drugs and devices get to market faster than ever.
Technical Considerations
The FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) require that submitted documentation meets their electronic common technical document (eCTD) format. In addition, the software used to create the regulatory submissions need to follow 21 CFR 11. While these requirements may seem stringent, the goal is to ensure that Life Sciences organizations have control over their data, including who enters it and who modifies it. The FDA also wants to ensure that the appropriate people can quickly and accurately access the data. Overall, there needs to be controlled processes for generating this data. The technology used is mission-critical and typically part of a strictly validated environment where everything is documented.
Conquer FDA Form 1572
There are thousands of documents that come from clinical trials that can benefit from the kind of automation technology Adlib offers. As an example, teams responsible for submitting new medicines to the FDA are already familiar with Form 1572, which ensures compliance with the FDA Code of Federal Regulations. The purpose of the form is meant to help document clinical trials. However, manually compiling data from hundreds of FDA 1572 forms is a time-consuming burden.
AI models can now automatically identify not only that a document is a form 1572 but can also classify and extract the essential data that enables companies to accelerate document handling and meet FDA expectations consistently.
Land Submissions the First Time With Adlib
PDFs generated using the Adlib document transformation platform meet both the technical requirements for PDF submission and are compliant with the FDA and EU requirements for the use of electronic systems. Adlib offers an enterprise-grade rendering solution that meets and exceeds the requirements for compliant FDA submission, including:
The Adlib platform‘s 15+ year track record has enabled pharma companies to automatically convert regulatory-compliant documents at scale into searchable, standardized PDF formats to navigate FDA submissions with confidence, accuracy, and ease.